Journal article
ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer
World journal of urology, Vol.37(1), pp.51-60
01/2019
DOI: 10.1007/s00345-018-2438-9
PMID: 30109483
Abstract
To provide a summary of the Third International Consultation on Bladder Cancer recommendations for the management of non-muscle invasive bladder cancer (NMIBC).
A detailed review of the literature was performed focusing on original articles for the management of NMIBC. An international committee assessed and graded the articles based on the Oxford Centre for Evidence-based Medicine system. The entire spectrum of NMIBC was covered such as prognostic factors of recurrence and progression, risk stratification, staging, management of positive urine cytology with negative white light cystoscopy, indications of bladder and prostatic urethral biopsies, management of Ta low grade (LG) and high risk tumors (Ta high grade [HG], T1, carcinoma in situ [CIS]), impact of BCG strain and host on outcomes, management of complications of intravesical therapy, role of alternative therapies, indications for early cystectomy, surveillance strategies, and new treatments. The working group provides several recommendations on the management of NMIBC.
Recommendations were summarized with regard to staging; management of primary and recurrent LG Ta and high risk disease, positive urine cytology with negative white light cystoscopy and prostatic urethral involvement; indications for timely cystectomy; and surveillance strategies.
NMIBC remains a common and challenging malignancy to manage. Accurate staging, grading, and risk stratification are critical determinants of the management and outcomes of these patients. Current tools for risk stratification are limited but informative, and should be used in clinical practice when determining diagnosis, surveillance, and treatment of NMIBC.
Details
- Title: Subtitle
- ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer
- Creators
- Leonardo L Monteiro - McGill UniversityJ Alfred Witjes - Radboud University Medical CenterPiyush K Agarwal - National Institutes of HealthChristopher B Anderson - Columbia UniversityTrinity J Bivalacqua - Johns Hopkins MedicineBernard H Bochner - Memorial Sloan Kettering Cancer CenterJoost L Boormans - Erasmus MC Cancer InstituteSam S Chang - Vanderbilt UniversityJose L Domínguez-Escrig - Fundación Instituto Valenciano de OncologíaJames M McKiernan - Columbia UniversityColin Dinney - Department of Urology, MD Anderson Cancer Center, Houston, USAGuilherme Godoy - Baylor College of MedicineGirish S Kulkarni - Princess Margaret Cancer CentreParamananthan Mariappan - Western General HospitalMichael A O'Donnell - University of IowaCyrill A Rentsch - University of BaselJay B Shah - Stanford UniversityEduardo Solsona - Fundación Instituto Valenciano de OncologíaRobert S Svatek - Department of Urology, Division of Urologic Oncology, The University of Texas Health San Antonio, San Antonio, USAAntoine G van der Heijden - Radboud University Medical CenterF Johannes P van Valenberg - Radboud University Medical CenterWassim Kassouf - McGill University
- Resource Type
- Journal article
- Publication Details
- World journal of urology, Vol.37(1), pp.51-60
- DOI
- 10.1007/s00345-018-2438-9
- PMID
- 30109483
- ISSN
- 0724-4983
- eISSN
- 1433-8726
- Language
- English
- Date published
- 01/2019
- Academic Unit
- Urology
- Record Identifier
- 9984320856002771
Metrics
18 Record Views